Newron Pharmaceuticals S.p.A. (ETR:NP5)
Germany flag Germany · Delayed Price · Currency is EUR
7.63
-0.19 (-2.43%)
Apr 24, 2025, 5:35 PM CET

Newron Pharmaceuticals Ratios and Metrics

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Apr '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Market Capitalization
15518695282835
Upgrade
Market Cap Growth
95.60%95.60%239.07%0.38%-21.34%-66.00%
Upgrade
Enterprise Value
196223126443322
Upgrade
Last Close Price
7.829.415.301.511.531.98
Upgrade
PE Ratio
9.8011.72----
Upgrade
PS Ratio
3.023.6110.484.594.846.74
Upgrade
PB Ratio
106.51127.32-3.17-1.998.982.06
Upgrade
P/TBV Ratio
106.51127.32--8.982.06
Upgrade
EV/Sales Ratio
3.814.3413.957.265.774.13
Upgrade
EV/EBITDA Ratio
7.438.52----
Upgrade
EV/EBIT Ratio
7.498.53----
Upgrade
Debt / Equity Ratio
34.6234.62-1.62-3.2513.871.53
Upgrade
Debt / EBITDA Ratio
1.911.91----
Upgrade
Asset Turnover
1.151.150.290.140.110.09
Upgrade
Quick Ratio
2.422.420.625.5010.585.50
Upgrade
Current Ratio
2.602.600.685.6510.795.50
Upgrade
Return on Equity (ROE)
-----146.43%-77.71%
Upgrade
Return on Assets (ROA)
36.44%36.44%-23.05%-18.96%-15.19%-20.26%
Upgrade
Return on Capital (ROIC)
46.45%46.45%-28.99%-21.37%-17.21%-23.21%
Upgrade
Return on Capital Employed (ROCE)
64.80%64.80%----
Upgrade
Earnings Yield
10.20%8.54%-17.09%-62.50%-53.44%-59.23%
Upgrade
FCF Yield
-11.35%-9.50%-10.70%-39.69%-41.12%-44.07%
Upgrade
Buyback Yield / Dilution
-15.30%-15.30%----
Upgrade
Updated Sep 19, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.